These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25793625)

  • 61. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
    Montaner M; Lopez-Argüello S; Oliver A; Moya B
    Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
    Biedenbach DJ; Johnson DM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa.
    Williams RJ; Livermore DM; Lindridge MA; Said AA; Williams JD
    J Med Microbiol; 1984 Jun; 17(3):283-93. PubMed ID: 6327987
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence of inducible beta-lactamases in gram-negative septicemia isolates from twenty-nine European laboratories. European Study Group on Antibiotic Resistance.
    Eur J Clin Microbiol; 1987 Aug; 6(4):460-6. PubMed ID: 3117535
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant
    Contreras-Gómez MJ; Martinez JRW; Rivas L; Riquelme-Neira R; Ugalde JA; Wozniak A; García P; Munita JM; Olivares-Pacheco J; Alcalde-Rico M
    Front Pharmacol; 2022; 13():1007162. PubMed ID: 36263116
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
    Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Plasmid-Mediated AmpC β-Lactamase and Underestimation of Extended-Spectrum β-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates.
    Nishimura F; Morinaga Y; Akamatsu N; Matsuda J; Kaku N; Takeda K; Uno N; Kosai K; Hasegawa H; Yanagihara K
    Jpn J Infect Dis; 2018 Jul; 71(4):281-285. PubMed ID: 29709981
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
    Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
    J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
    Aktaş Z; Satana D; Kayacan C; Can B; Gönüllü N; Küçükbasmacı O
    Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.